Jump to content
IndiaDivine.org

Fwd: Safety For Sale

Rate this topic


Guest guest

Recommended Posts

Guest guest

Mon, 12 Apr 2004 12:51:34 -0500

HSI - Jenny Thompson

Safety For Sale

 

Safety For Sale

 

Health Sciences Institute e-Alert

 

April 12, 2004

 

************************************************************

 

Dear Member,

 

It's rare to get a glimpse of the inner workings of the FDA. But the growing

controversy surrounding suicides among minors taking antidepressant drugs

reveals disturbing priorities when the issue of safety comes into conflict with

the agency's close relationship with the drug industry.

 

And now Congress is turning up the heat. The U.S. House of Representatives

Energy and Commerce Committee has launched an investigation to determine if FDA

officials acted in a timely manner in demanding warnings about the association

between antidepressants and suicide among the young.

 

As the old saw goes: Where's there's smoke, there's fire.

 

----------------------------

Strike a match

----------------------------

 

Last month the FDA asked manufacturers of several prominent antidepressant drugs

to include in the product labeling, " a warning statement that recommends close

observation of adult and pediatric patients... for worsening depression or the

emergence of suicidality. "

 

But as CBS reports, the full FDA statement implies that there is really no

strong evidence that these drugs prompt suicide among the young, even though a

safety analysis by an FDA medical officer revealed that just the opposite is

true.

 

Here's the sequence of events, as described by CBS News:

 

In the summer of 2003, reports from GlaxoSmithKline (GSK - maker of Paxil)

indicated an association between antidepressant use and suicide among minors in

clinical trials. An FDA internal document stated that the information, " had us

worried. "

 

In response to the GSK data, Dr. Andrew Mosholder, an FDA medical officer and

child psychiatrist, performed a safety analysis, reviewing 20 studies that

examined the outcomes of more than 4,100 children who used eight different

brands of antidepressants. The San Francisco Chronicle reports that Dr.

Mosholder's analysis found a clear risk of increased suicidal behavior among

children taking antidepressants.

 

----------------------------

Asking the hard questions

----------------------------

 

CBS News states that the Mosholder analysis indicated two times as many

suicide-related events occurred among those children who took antidepressants,

compared to those taking placebo. (This simple observation sidetracks a

prevalent theory that it's not the drugs prompting the suicides but rather the

fact that depressed minors already have a tendency toward suicidal thoughts.)

 

Although Dr. Mosholder characterized these findings as " difficult to dismiss, "

FDA officials removed his report from the agenda when a special panel reviewed

evidence about antidepressant use among minors last February.

 

One FDA insider asked this question when interviewed by the San Francisco

Chronicle: " Why is the agency sitting on its hands and acting as if there isn't

a risk when their own scientists have looked at the data and concluded that

there is? "

 

Excellent question.

 

And all the more important because it comes from within the agency.

 

----------------------------

Just say, " No! "

----------------------------

 

The FDA makes a big deal out of protecting minors with the absurd ban of ephedra

products. But when it comes to some of the best-selling drugs on the market

today, who is the FDA protecting?

 

The CBS report quotes Vera Hassner Sharav, the president of the Alliance for

Human Research Protection, who stated simply that officials at the FDA are

watching out for the drug industry, not consumers.

 

But the fact is, we don't need further FDA warnings. For one thing, we've

already got the important information we need from Dr. Mosholder (thank you, CBS

News). And for another thing, just how effective can warning labels really be?

Antidepressant drug use among minors is quickly approaching adult usage rates in

spite of existing labels. Is an additional warning really going to put a dent in

those sales?

 

Besides, we already know exactly what to do: Stop drugging our children!

 

These kids should be getting one-on-one counseling, altering their diets, and,

if need be, trying safe, non- pharmaceutical means of controlling depression

(such as St. John's Wort) before a single drug prescription is ever written.

 

In the meantime, the House Energy and Commerce Committee may decide to step over

the FDA and issue requirements for more explicit warnings on the labels of

antidepressant drugs. Frankly, this strikes me as election-year posing - a

little saber-rattling for the constituents back home. But if it serves to help

keep this controversy alive, that's a positive step. When this sort of thing

becomes water-cooler conversation, the public gets a better education than any

number of mandated warning labels could provide.

 

************************************************************ To start receiving

your own copy of the HSI e-Alert, visit:

http://www.hsibaltimore.com/ealert/freecopy_bnyt.html Or forward this e-mail to

a friend so they can sign-up to receive their own copy of the HSI e-Alert.

 

************************************************************

 

To Your Good Health,

 

Jenny Thompson

Health Sciences Institute

 

************************************************************

************************************************************

To start receiving your own copy of the HSI e-Alert, visit:

http://www.hsibaltimore.com/ealert/freecopy_bnyb.html Or forward this e-mail to

a friend so they can sign-up to receive their own copy of the HSI e-Alert.

 

************************************************************

 

Sources:

" FDA Mum on Suicidal Side Effects? " Sharyl Attkisson, CBS News, 3/30/04,

cbsnews.com

" Drug Report Barred by FDA - Scientist Links Antidepressants to Suicide in Kids "

Rob Waters, San Francisco Chronicle, 2/1/04, sfgate.com

" Panel Probes FDA Moves on Antidepressant Risks " Reuters, 3/24/04, reuters.com

" Worsening Depression and Suicidality in Patients Being Treated with

Antidepressant Medications " FDA Public Health Advisory, 3/22/04, fda.gov

" Most Low-Carb Dieters Eat Too Many Carbs - Study " Reuters Health, 4/5/04,

reutershealth.com

 

Copyright ©1997-2004 by www.hsibaltimore.com, L.L.C. The e-Alert may not be

posted on commercial sites without written permission.

 

************************************************************

Before you hit reply to send us a question or request, please visit here

http://www.hsibaltimore.com/ealert/questions.html

 

************************************************************

If you'd like to participate in the HSI Forum, search past e-Alerts and products

or you're an HSI member and would like to search past articles, visit

http://www.hsibaltimore.com

 

************************************************************

 

 

 

 

 

 

Tax Center - File online by April 15th

 

 

Link to comment
Share on other sites

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...